<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163293</url>
  </required_header>
  <id_info>
    <org_study_id>BY9010/CA-101</org_study_id>
    <nct_id>NCT00163293</nct_id>
  </id_info>
  <brief_title>Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 y) (BY9010/CA-101)</brief_title>
  <acronym>POPCICLE</acronym>
  <official_title>Effect of Low Dose Continuous Treatment With Ciclesonide Over One Year on the Time to First Exacerbation in Children With Mild Asthma Versus Intermittent Treatment for Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of ciclesonide with respect to reduction of
      the number of asthma exacerbations in children with mild persistent asthma. Treatment
      medication will be administered as follows: ciclesonide will be inhaled once daily, using
      one of the two dose levels versus placebo together with other corticosteroids used as
      intermittent treatment. The study duration consists of a baseline period (3 to 4 weeks) and
      a treatment period (12 months). The study will provide further data on safety and
      tolerability of ciclesonide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to First Exacerbation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Basis was the Intention to Treat Population (ITT). Time to first exacerbation is defined as the time until the first asthma exacerbation, or to end of T12 visit (=last visit).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exacerbations (Post-hoc Analysis of Annual Rates)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A model-based analysis of asthma exacerbation was performed to adjust to important covariables. The distribution of the data suggested a Poisson regression modeling (zero inflated) strategy.
After a variable selection process considering also variable-by-treatment interactions, the variables centre, age [yrs] and race were identified to be important beside treatment.
The parameters centre and age [yrs] were allocated to zero-model part and the variables treatment and race to the Poisson model part.
The estimates of the per-treatment rates are based on a negative-binomial distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth Velocity as Assessed by Stadiometric Height Measurement</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Standing height measured in millimeters with a wall-mounted stadiometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rate of Asthma Exacerbations Per Year</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Exacerbations</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Exacerbations</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop-out Rate Due to Asthma Exacerbation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 as Percent Predicted and Absolute Values</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning and Evening PEF Measurements by Diary Entries</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in PEF by Diary Entries</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diurnal PEF Fluctuation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Score by Diary Entries</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Nights With Nocturnal Awakenings Due to Asthma Symptoms</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use by Diary Entries</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Rescue Medication Free Days by Diary Entries</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of rescue medication free days is the number of days during which the total puffs of rescue medication (salbutamol) use is 0.
Assessment during baseline period at visit B2, B3 and B4 and during treatment period at visit T1, T2, T4, T6, T8, T10 and T12/Tend.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptom Free Days by Diary Entries</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessments as Per Pediatric Asthma Quality of Life Questionnaires PAQLQ(S) and PACQLQ</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination and Vital Signs</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Work-up.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CIC 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciclesonide 100µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIC 200</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciclesonide 200µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>100µg, two puffs once daily, in the evening</description>
    <arm_group_label>CIC 100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>200µg, two puffs once daily, in the evening</description>
    <arm_group_label>CIC 200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>two puffs once daily, in the evening</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Outpatients

          -  Symptoms consistent with the diagnosis of asthma for at least 12 months

          -  FEV1 at least 80% of predicted

          -  Patients who have a history of reversible airway obstruction

          -  Good health with the exception of asthma

        Main Exclusion Criteria:

          -  History of life-threatening asthma

          -  A hospitalization for asthma within the last 3 months, or more than two
             hospitalizations for asthma within the last year

          -  Concomitant severe diseases or diseases which are contraindications for the use of
             inhaled steroids

          -  Patients suffering from relevant lung diseases causing alternating impairment in lung
             function (e.g. chronic bronchitis or emphysema)

          -  Prematurely born children (&lt;36 weeks of gestation)

          -  Smokers

          -  Pregnancy (or intention to become pregnant during the course of the trial), breast
             feeding or lack of safe contraception by female of child-bearing potential
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Becker, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital, Winnipeg, Manitoba, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Calgary</city>
        <zip>T2T5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Fleurimont</city>
        <zip>J1H 5M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>London,ON</city>
        <zip>N6A1V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>London</city>
        <zip>N6C 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Kapstadt</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <lastchanged_date>May 4, 2012</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <firstreceived_results_date>December 1, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Nycomed GmbH</name_title>
    <organization>Nycomed</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Ciclesonide</keyword>
  <keyword>Exacerbation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient in the placebo treatment group was randomized but did not receive a dose of study drug, so was excluded from the Safety Analysis Set in Baseline Characteristics.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CIC 100</title>
          <description>Ciclesonide 100µg, two puffs once daily, in the evening</description>
        </group>
        <group group_id="P2">
          <title>CIC 200</title>
          <description>Ciclesonide 200µg, two puffs once daily, in the evening</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>two puffs once daily, in the evening</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CIC 100</title>
          <description>Ciclesonide 100µg</description>
        </group>
        <group group_id="B2">
          <title>CIC 200</title>
          <description>Ciclesonide 200µg</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
                <measurement group_id="B2" value="76"/>
                <measurement group_id="B3" value="84"/>
                <measurement group_id="B4" value="239"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Basis was the Safety Analysis Set.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7.9" spread="2.06"/>
                <measurement group_id="B2" value="7.7" spread="1.84"/>
                <measurement group_id="B3" value="8.1" spread="2.19"/>
                <measurement group_id="B4" value="7.9" spread="2.04"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Basis was the Safety Analysis Set.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="34"/>
                <measurement group_id="B4" value="98"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="50"/>
                <measurement group_id="B4" value="141"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Basis was the Safety Analysis Set.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="59"/>
                <measurement group_id="B4" value="167"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Basis was the Safety Analysis Set.</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.90" spread="9.701"/>
                <measurement group_id="B2" value="30.01" spread="9.247"/>
                <measurement group_id="B3" value="33.13" spread="11.640"/>
                <measurement group_id="B4" value="31.08" spread="10.365"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Basis was the Safety Analysis Set.</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17.30" spread="3.107"/>
                <measurement group_id="B2" value="17.69" spread="2.977"/>
                <measurement group_id="B3" value="18.68" spread="4.069"/>
                <measurement group_id="B4" value="17.91" spread="3.478"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Exacerbation</title>
        <description>Basis was the Intention to Treat Population (ITT). Time to first exacerbation is defined as the time until the first asthma exacerbation, or to end of T12 visit (=last visit).</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Basis is the Intention to Treat (ITT) population. The ITT-analysis is based on those patients of the full analysis set having at least one post-baseline measurement of the primary efficacy outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>CIC 100</title>
            <description>Ciclesonide 100µg</description>
          </group>
          <group group_id="O2">
            <title>CIC 200</title>
            <description>Ciclesonide 200µg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="76"/>
                  <measurement group_id="O3" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First Exacerbation</title>
            <description>Basis was the Intention to Treat Population (ITT). Time to first exacerbation is defined as the time until the first asthma exacerbation, or to end of T12 visit (=last visit).</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="225.1" spread="14.73"/>
                  <measurement group_id="O2" value="249.5" spread="14.79"/>
                  <measurement group_id="O3" value="227.2" spread="15.20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6625</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.7303</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Velocity as Assessed by Stadiometric Height Measurement</title>
        <description>Standing height measured in millimeters with a wall-mounted stadiometer</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>CIC 100</title>
            <description>Ciclesonide 100µg</description>
          </group>
          <group group_id="O2">
            <title>CIC 200</title>
            <description>Ciclesonide 200µg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="76"/>
                  <measurement group_id="O3" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Growth Velocity as Assessed by Stadiometric Height Measurement</title>
            <description>Standing height measured in millimeters with a wall-mounted stadiometer</description>
            <units>mm/year</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55.32" spread="25.81"/>
                  <measurement group_id="O2" value="64.60" spread="27.31"/>
                  <measurement group_id="O3" value="54.91" spread="21.78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rate of Asthma Exacerbations Per Year</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Exacerbations</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Exacerbations</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drop-out Rate Due to Asthma Exacerbation</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1 as Percent Predicted and Absolute Values</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning and Evening PEF Measurements by Diary Entries</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in PEF by Diary Entries</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diurnal PEF Fluctuation</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Symptom Score by Diary Entries</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Nights With Nocturnal Awakenings Due to Asthma Symptoms</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use by Diary Entries</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Rescue Medication Free Days by Diary Entries</title>
        <description>The number of rescue medication free days is the number of days during which the total puffs of rescue medication (salbutamol) use is 0.
Assessment during baseline period at visit B2, B3 and B4 and during treatment period at visit T1, T2, T4, T6, T8, T10 and T12/Tend.</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptom Free Days by Diary Entries</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessments as Per Pediatric Asthma Quality of Life Questionnaires PAQLQ(S) and PACQLQ</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Examination and Vital Signs</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Work-up.</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exacerbations (Post-hoc Analysis of Annual Rates)</title>
        <description>A model-based analysis of asthma exacerbation was performed to adjust to important covariables. The distribution of the data suggested a Poisson regression modeling (zero inflated) strategy.
After a variable selection process considering also variable-by-treatment interactions, the variables centre, age [yrs] and race were identified to be important beside treatment.
The parameters centre and age [yrs] were allocated to zero-model part and the variables treatment and race to the Poisson model part.
The estimates of the per-treatment rates are based on a negative-binomial distribution.</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>CIC 100</title>
            <description>Ciclesonide 100µg</description>
          </group>
          <group group_id="O2">
            <title>CIC 200</title>
            <description>Ciclesonide 200µg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="76"/>
                  <measurement group_id="O3" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Exacerbations (Post-hoc Analysis of Annual Rates)</title>
            <description>A model-based analysis of asthma exacerbation was performed to adjust to important covariables. The distribution of the data suggested a Poisson regression modeling (zero inflated) strategy.
After a variable selection process considering also variable-by-treatment interactions, the variables centre, age [yrs] and race were identified to be important beside treatment.
The parameters centre and age [yrs] were allocated to zero-model part and the variables treatment and race to the Poisson model part.
The estimates of the per-treatment rates are based on a negative-binomial distribution.</description>
            <units>number of events per year</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.93" spread="0.29"/>
                  <measurement group_id="O2" value="0.88" spread="0.27"/>
                  <measurement group_id="O3" value="1.26" spread="0.28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1291</p_value>
            <method>Wald Chi-square</method>
            <method_desc>zero inflated Poisson model: adjustment for centre and age [yrs] (zero model), treatment and race (Poisson model)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0145</p_value>
            <method>Wald Chi-square</method>
            <method_desc>zero inflated Poisson model: adjustment for centre and age [yrs] (zero model), treatment and race (Poisson model)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The numbers of subjects at risk are based on the Safety Population. It was based on all randomized patients receiving at least one dose of the double-blind study medication after randomization.
All adverse events and serious adverse events were coded according to the currently valid MedDRA versions 8.0, 8.1, 9.0 and 9.1.</desc>
      <group_list>
        <group group_id="E1">
          <title>CIC 100</title>
          <description>Ciclesonide 100µg, two puffs once daily, in the evening</description>
        </group>
        <group group_id="E2">
          <title>CIC 200</title>
          <description>Ciclesonide 200µg, two puffs once daily, in the evening</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>two puffs once daily, in the evening</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Myringoplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" events="18" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E3" events="30" subjects_affected="14" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="79"/>
                <counts group_id="E2" events="31" subjects_affected="19" subjects_at_risk="76"/>
                <counts group_id="E3" events="35" subjects_affected="16" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" events="60" subjects_affected="35" subjects_at_risk="79"/>
                <counts group_id="E2" events="64" subjects_affected="38" subjects_at_risk="76"/>
                <counts group_id="E3" events="82" subjects_affected="39" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Advisor</name_or_title>
      <organization>Nycomed GmbH</organization>
      <phone>0049-7531-840</phone>
      <email>clinicaltrials@nycomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
